Original articlesSupportive carePalonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
Supportive care
Under an Elsevier user license
open archive
Keywords
chemotherapy-induced nausea and vomiting
emesis
5-HT3 receptor antagonist
ondansetron
palonosetron
Cited by (0)
Copyright © 2003 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.